Brenner, Ellen

1. General information

Name Brenner, Ellen, Dr. rer. nat., female

Date of Birth 10.03.1982

Work address Universitätsklinikum Tübingen, IM8

Universität Tübingen

iFIT, Röntgenweg 11, 72076 Tübingen

Contact details 🕾 07071/29-86219, 📧 ellen.brenner@med.uni-tuebingen.de

Current position and status Executive Manager

1. University training and degree

2009 Diploma thesis at the Dermatology Tübingen in cooperation with the University of Stuttgart: Role of TLR/MyD88- signaling in metastasis  
Mentor: Prof. Dr. Dagmar Kulms and Dr. Regina Heidenreich

2008 Assignment at the Institute of Technical Biochemistry, Stuttgart: Intracellular Expression of human Cytochrom P450 Monooxygenases 2D6 and 3A4 in Pichia pastoris  
Mentor: Dr. Stefan Lange

2001 - 2009 University training in Technical Biology at the University of Stuttgart, major in Immunology and Cell Biology, minor in Technical Biochemistry and Industrial Genetics

1. Advanced academic qualifications

2013 – 2021 Doctorate: PhD at the Faculty of Science in Biology at the University of Tübingen: “Cancer Immunotherapy Requires Interferon-dependent Senescence Induction”  
Mentor: Prof. Dr. M. Röcken and Hans-Georg Rammensee

1. Postgraduate professional career

2024 – present Executive Manager of the Cluster of Excellence iFIT Image-guided and Functionally Instructed Tumor Therapies, EXC 2180, University Tübingen

2021 – 2023 Postdoc of the research group Tumorimmunology at the Department of Dermatology, University Hospital Tübingen

2013 – 2021 PhD thesis at the Faculty of Science in Biology at the University of Tübingen

2009 – 2013 Scientific assistant of Dr. Regina Heidenreich of the research group Experimental Angiology at the Department of Dermatology, University Hospital Tübingen

1. Other

2022 Project manager of the genetic engineering facility

2019 Poster Prize, European Society for Dermatology Research (ESDR), Bordeaux, France

2016 Travel fellowship to the annual meeting of the Society for Investigative Dermatology (SID) as conference speaker, Scottsdale, USA

2016 Dermato-Oncology Young Investigators Award, Arbeitsgemeinschaft Dermatologische Forschung (ESDR), Wien, Austria

2008 Basic Course on Laboratory Animal Science, Eberhard Karls University of Tübingen, Germany (Qualification equivalent to FELASA B)

1. Publications

a) Journal publications and book contributions

1. Homann L, Rentschler M, **Brenner E**, Böhm K, Röcken M and Wieder T. IFN-γ and TNF Induce Senescence and a Distinct Senescence-Associated Secretory Phenotype in Melanoma. *Cells* 2022, *11*, doi:10.3390/cells11091514.

2. **Brenner E** and Röcken M. A Commotion in the Skin: Developing Melanoma Immunotherapies. *J. Invest. Dermatol.* 2022, 10.1016/j.jid.2022.01.025, doi:10.1016/j.jid.2022.01.025.

3. Ahmetlic F, Fauser J, Riedel T, Bauer V, Flessner C, Hömberg N, Hennel R, **Brenner E**, Lauber K, Röcken M and Mocikat R. Therapy of lymphoma by immune checkpoint inhibitors: the role of T cells, NK cells and cytokine-induced tumor senescence. *Journal for immunotherapy of cancer* 2021, *9*, doi:10.1136/jitc-2020-001660.

4. **Brenner E**, Schorg BF, Ahmetlic F, Wieder T, Hilke FJ, Simon N, Schroeder C, Demidov G, Riedel T, Fehrenbacher B, Schaller M, Forschner A, Eigentler T, Niessner H, Sinnberg T, Bohm KS, Homberg N, Braumuller H, Dauch D, Zwirner S, Zender L, Sonanini D, Geishauser A, Bauer J, Eichner M, Jarick KJ, Beilhack A, Biskup S, Docker D, Schadendorf D, Quintanilla-Martinez L, Pichler BJ, Kneilling M, Mocikat R and Rocken M. Cancer immune control needs senescence induction by interferon-dependent cell cycle regulator pathways in tumours. *Nature communications* 2020, *11*, 1335, doi:10.1038/s41467-020-14987-6.

5. Wieder T, Eigentler T, **Brenner E** and Rocken M. Immune checkpoint blockade therapy. *J. Allergy Clin. Immunol.* 2018, *142*, 1403-1414, doi:10.1016/j.jaci.2018.02.042.

6. Rentschler M, Chen Y, Pahl J, Soria-Martinez L, Braumuller H, **Brenner E**, Bischof O, Rocken M and Wieder T. Nuclear translocation of argonaute 2 in cytokine-induced senescence. *Cell. Physiol. Biochem.* 2018, *51*, 1103-1118, doi:10.1159/000495490.

7. Wieder T, **Brenner E**, Braumuller H, Bischof O and Rocken M. Cytokine-induced senescence for cancer surveillance. *Cancer Metastasis Rev.* 2017, *36*, 357-365, doi:10.1007/s10555-017-9667-z.

8. Wieder T, **Brenner E**, Braumuller H and Rocken M. Immunotherapy of melanoma: efficacy and mode of action. *J Dtsch Dermatol Ges* 2016, *14*, 28-36, doi:10.1111/ddg.12819.

9. Wieder T, Braumuller H, **Brenner E**, Zender L and Rocken M. Changing T-cell enigma: cancer killing or cancer control? *Cell Cycle* 2013, *12*, 3146-3153, doi:10.4161/cc.26060.

10. Braumuller H, Wieder T, **Brenner E**, Assmann S, Hahn M, Alkhaled M, Schilbach K, Essmann F, Kneilling M, Griessinger C, Ranta F, Ullrich S, Mocikat R, Braungart K, Mehra T, Fehrenbacher B, Berdel J, Niessner H, Meier F, van den Broek M, Haring HU, Handgretinger R, Quintanilla-Martinez L, Fend F, Pesic M, Bauer J, Zender L, Schaller M, Schulze-Osthoff K and Rocken M. T-helper-1-cell cytokines drive cancer into senescence. *Nature* 2013, *494*, 361-365, doi:10.1038/nature11824.

b) Other publications: none

c) Patents:

JPWO 2022-509000   
 Method for classifying a patient's responsiveness to immune checkpoint inhibitor therapy

US 10,046,029 B2  
 Method of inducing senescence in tumour cells by administrating TNF-A in combination with IFN-A of IFN-Y

EU 13 826 993.1  
 Use of active substance combinations for tumour senescence

PCT/DE 2013/000794 Verwendung von Wirkstoffkombinationen zur Induktion einer Tumorseneszenz